TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05411016
Drug: KK4277
Approvals — FDA: no, EMA: no, PMDA: no
Description: KK4277 is administered single dose or multiple dose by IV or SC injection
Study: NCT05052268
Drug: XTX202
Approvals — FDA: no, EMA: no, PMDA: no
Description: XTX202 Monotherapy
Study: NCT00000794
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000794
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06497439
Drug: Placebo tablet of Silfamin
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of Silfamin Placebo twice daily
Study: NCT06248008
Drug: ASC40
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASC40 tablets orally once daily
Study: NCT05811442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active study drug
Study: NCT05272384
Drug: Decitabine and Cedazuridine
Normalized name: cedazuridine / decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05077215
Drug: EG-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Repurposed Drug
Study: NCT04762511
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of placebo (saline) administered intramuscularly in the non-dominant arm, one each at Day 1 and Day 57.
Study: NCT05519475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by SC injection
Study: NCT06276465
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous ADT during the study course. The choice of ADT is left to the discretion of the investigator.
Study: NCT05960240
Drug: AB-101
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB-101 is an oral small molecule PD-L1 checkpoint inhibitor being developed for the treatment of chronic infection with HBV in combination with other agents.
Study: NCT05960240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo is any treatment that has no active properties, such as a sugar pill. We will use matching placebo for this study.
Study: NCT05960240
Drug: Nucleos(t)ide Analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B.
Study: NCT06270147
Drug: Bupivacaine-epinephrine
Normalized name: bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.
Study: NCT05897541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a tablet.
Study: NCT05972720
Drug: Cyclophosphamide Monohydrate (Conditional therapy)
Normalized name: cyclophosphamide monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepletion chemotherapy
Study: NCT05935553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * placebo capsule (for the placebo arm)~* Dosage:3 capsules of placebo per day~* route of administration: Oral~* duration of treatment: Total duration of treatment is 13 weeks including 1 week of dose escalation, 11 weeks of maintenance at full dose, and 1 week of dose de-escalation
Study: NCT05539027
Drug: Branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA)
Study: NCT05270668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05383079
Drug: Lutetium-177 PSMA-I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles
Study: NCT06220032
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 Cycle 1-6: 750 mg/m2 (iv)
Study: NCT06220032
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 Cycle 1-6: 50 mg/m2 (iv)
Study: NCT06220032
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1-5 Cycle 1-6: 100 mg (oral)
Study: NCT04857372
Drug: IAG933
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT05645718
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by (IV) vein
Study: NCT05645718
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by (IV) vein
Study: NCT06601608
Drug: Herbal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosemary extract gel is used for the first time as a local drug delivery as an adjunct to non-surgical periodontal therapy in management of stage III periodontitis patients.
Study: NCT06601608
Drug: Placebo Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: a placebo gel will be applied in deep pockets (\&gt;5mm) in stage III periodontitis patients as an adjunct to non-surgical periodontal therapy
Study: NCT05645718
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by (IV) vein
Study: NCT05472090
Drug: Placebo SL Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study: NCT06062420
Drug: GSK4381562
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4381562 will be administered.
Study: NCT06017999
Drug: XG005 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive XG005 prior to surgery and every 12 hours for 72 hours.
Study: NCT06017999
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo prior to surgery and every 12 hours for 72 hours.
Study: NCT06705777
Drug: Combinations
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, and Rutin combination
Study: NCT06705686
Drug: (R)-9bMS
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-9bMS will be given in clinic on day 1, two doses 12 hours (+/- 30 minutes) apart, and on day 2, 12 hours (+/- 30 minutes) after the second day 1 dose. Patients will be admitted overnight for these first 3 doses. Patient must be fasting 1 hour before and 1 hour after doses for these first 3 doses. (R)-9bMS should be taken with a glass of water. Patients will be dispensed home supply after C1D2 morning dose.
Study: NCT06375044
Drug: SIM0500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive SIM0500 in a 28-day cycle until disease progression, intolerable toxicity, or until the participant voluntarily withdraws from trial intervention, or end of study, whichever comes first.
Study: NCT04880642
Drug: C21
Normalized name: C18-C21 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21
Study: NCT04880642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05431270
Drug: Mavrostobart (PT199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action.
Study: NCT04696120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients who are assigned to placebo group will receive placebo
Study: NCT06058000
Drug: 1.5% QLM3003
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLM3003 topical cream
Study: NCT06058000
Drug: 2% QLM3003
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLM3003 topical cream
Study: NCT05746429
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo sham tDCS
Study: NCT06111313
Drug: ADT Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive ADT as per standard of care (SOC).
Study: NCT05874570
Drug: Tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT05874570
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT05278611
Drug: EP-9001A
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of the study was set as 1 mg, and the doses were escalated sequentially in the order of 1 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, and 25 mg
Study: NCT05278611
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05629052
Drug: Pulmonary hypertension (PH)-specific medication
Normalized name: Antihypertensives for pulmonary arterial hypertension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with any PH-specific medication, i.e. endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, drugs acting on the prostanoid pathway and prostaglandin I2 receptor agonists
Study: NCT05371249
Drug: Extended sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30mg + amoxicillin 1000mg twice daily for 7 days, followed by lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg twice daily for 7 days
Study: NCT00000175
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05889728
Drug: [68Ga]GA-NeoB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Is a positron emission tomography (PET) imaging agent, intended as a selection tool for \[177Lu\]Lu-NeoB treatment in patients with tumors overexpressing gastrin releasing peptide receptor (GRPR).
Study: NCT06458712
Drug: DSB2455
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP1 inhibitor
Study: NCT05252884
Drug: routine postoperative calcium and calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient will receive a dose of 1,200 mg Calcium carbonate every 8 hours + 0.25 mcg of calcitriol every 12 hours orally for 15 days, starting on the same day as the intervention.
Study: NCT06611423
Drug: Dopamine
Normalized name: Dopamine
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine Hydrochloride 50mg/5mL
Study: NCT06164613
Drug: Cinnamomum Verum oil extract
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule of 1000 mg orally of Cinnamomum Verum oil extract per day for 21-28 days
Study: NCT06164613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg PO Canola oil soft gel capsule
Study: NCT06574009
Drug: Medication optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medications will be optimized following an algorithm the investigators created based upon NCCN's Survivorship Guidelines and AHRQ's comprehensive review of non-opioid treatments for chronic pain.
Study: NCT04469699
Drug: Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ALA HCl orally (20 mg/kg bw) 3,5-4,5 hours prior to induction of anaesthesia for stereotactic biopsy followed by stereotactical photodynamic therapy. All patients will receive further treatment of recurrent glioblastoma at the investigator´s discretion (best possible care).
Study: NCT06056102
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Safety Run-in: 375mg/m\^2 daily x 3~* Cohort 1: 375mg/m\^2 daily x 3~* Cohort 2: 375mg/m\^2 daily x 3~* Cohort 3: 375mg/m\^2 daily x 3
Study: NCT05828953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken orally once daily before breakfast. Taken continuously for 2 weeks, followed by a 1-week break, until week 52, disease progression, or the occurrence of intolerable adverse events. If a dose is missed and the next dose is due within 12 hours, it should not be made up.
Study: NCT06042764
Drug: SA55 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel coronavirus broad-spectrum neutralizing antibody SA55 injection (SA55 injection) is developed and produced by Beijing Kexing Zhongwei Biologics Technology Co., Ltd. The main component of SA55 injection is novel coronavirus broad-spectrum neutralizing antibody SA55. Each milliliter contains 150 mg of novel coronavirus broad-spectrum neutralizing antibody SA55. Excipients include histidine hydrochloride, arginine hydrochloride, histidine hydrochloride, sucrose, and polysorbate 80 (II)
Study: NCT05225402
Drug: Hemodynamic measurements during reduction in Norepinephrine and fluid boli.
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Extended monitoring equipment will be connected to the patient. Clinical and biochemical parameters will be collected for a baseline before the next step. A Safety check will be performed to ensure correct patient data, correct equipment function and safety measures are meet. A passive leg raise test will be performed to predict fluid responsiveness, in case of a positive test, a fluid challenge will be administered.~2. A stepwise reduction of the NE infusion rate from baseline while monitoring stroke volume (SV) to elucidate changes in SV and potential preloadresponsiveness. The reduction will occur in steps of 3-5 minute until either discontinuation of the norepinephrine infusion, a 50% reduction in SV or MAP\<40.~3. While maintaining the NE infusion rate from the previous step 2, a fluid challenge will be administrated, until additional fluid does not increase SV\>10%.~4. As in step 2, a stepwise increase in NE infusion rate to the baseline infusion level or the baseline BP.
Study: NCT05136976
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 infusions of placebo at a 2 week interval.
Study: NCT05136976
Drug: Premedications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premedications prior to rituximab or placebo infusions:~* IV Dexchlorpheniramine Maleate IV: 10 mg~* IV Methylprednisolone: 40 mg~* PO Paracetamol : 1 gram
Study: NCT06407934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Injection solution~Route of administration: SC injection
Study: NCT04333290
Drug: [11C]MeDAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET radiotracer
Study: NCT05132075
Drug: JDQ443
Approvals — FDA: no, EMA: no, PMDA: no
Description: JDQ443 tablets, orally administered
Study: NCT06252831
Drug: AS-Probionorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form - powder for the preparation of a solution for oral administration. Dosage regimen -1 sachet (1 g) take 2 times a day with an interval of 12 hours. Apply 15-20 minutes before meals in the morning and evening. Before use, the medicine is mixed with 30-50 ml of boiled water at room temperature, resulting in a cream-colored suspension. The resulting aqueous suspension should be drunk without achieving complete dissolution. The diluted drug cannot be stored. The duration of taking the medicine is 7 days. The study is carried out on an outpatient basis.~The total duration of each subject's participation in the clinical trial is no more than 21 ± 1 days. Throughout the entire study period, the research subject has the opportunity to contact the research team on all questions relating to the nature of this study. After completion of the entire observation period of 21 days, there is no follow-up of study subjects under the trial protocol.
Study: NCT04923347
Drug: FF/UMEC/VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI will be administered
Study: NCT04592874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion
Study: NCT05253209
Drug: Plasmalyte A
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Plasmalyte A given for up to 48 hours
Study: NCT05164120
Drug: Belnacasan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05164120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet containing 0mg of API
Study: NCT05698329
Drug: AIV007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocular injection
Study: NCT06423885
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration for a cycle of 3 weeks.
Study: NCT06160362
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 500mg/m2/day IV for 2 days(Day-3 to day-2).
Study: NCT05702463
Drug: Aspirin 81Mg Ec Tab twice daily for 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with incomplete platelet aggregation will be instructed to take EC ASA 81 mg twice daily for 7 days.
Study: NCT05676645
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: National policy recommendation for treatment of uncomplicated malaria in Uganda
Study: NCT05938023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose and scheduled as specified in the Arm description
Study: NCT05308420
Drug: Intrathecal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml of placebo solution (0.9%NaCl) is added to the local anesthetic solution injected for spinal anesthesia (total injectate volume 3.5ml)
Study: NCT05189535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05682170
Drug: ZN-d5 ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agent
Study: NCT05682170
Drug: ZN-c3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agent
Study: NCT06644755
Drug: DS-2243a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation Part: DS-2243a will be administered at escalating doses to determine the RDE~Expansion Part: DS-2243a will be administered at RDE
Study: NCT05381948
Drug: Eyp-1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection
Study: NCT06175767
Drug: MT101-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT06345495
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV
Study: NCT05769595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04497168
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo pills
Study: NCT05748873
Drug: SPVN06
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV-RdCVF-RdCVFL
Study: NCT04390217
Drug: LB1148
Approvals — FDA: no, EMA: no, PMDA: no
Description: LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
Study: NCT04390217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
Study: NCT06380153
Drug: Hemay005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1
Study: NCT05540938
Drug: Wangbi granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules 12.0g tid, treatment course 3 months.
Study: NCT05577754
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During double-blind period of group A: matching placebo will be taken once a day each day over 6 months
Study: NCT05540938
Drug: Wangbi granules simulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 7.5-15mg qw plus tofacitab 5mg bid, combined with Wangbi granules simulant 12.0g tid, treatment course 3 months.
Study: NCT05274568
Drug: [18F]UCB-2897
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container.
Study: NCT05738486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT04597424
Drug: Experimental: doxycycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days.
Study: NCT05044611
Drug: Anhydrous Amiloride Hydrochloride
Normalized name: amiloride hydrochloride, anhydrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride is a blocker of ENaC that is administered patients with various disorders, such as primary or secondary hyperaldosteronism. It does not have the market authorization in the indication of lithium-induced NDI.~Dose : 5 mg Pharmaceutical form: Tablets Daily Posology : 10 mg Route of administration : oral Procedures and duration of treatment: 2 months during the double blinded phase and 10 additional months for the open label phase
Study: NCT05044611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration : oral the control arm will receive a placebo twice daily during 2 months